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AbsTrACT
Objectives To detail the greatest areas of unmet 
scientific and clinical needs in rheumatology.
Methods The 21st annual international Advances in 
Targeted Therapies meeting brought together more than 
100 leading basic scientists and clinical researchers in 
rheumatology, immunology, epidemiology, molecular 
biology and other specialties. During the meeting, 
breakout sessions were convened, consisting of 5 
disease- specific groups with 20–30 experts assigned 
to each group based on expertise. Specific groups 
included: rheumatoid arthritis, psoriatic arthritis, axial 
spondyloarthritis, systemic lupus erythematosus and 
other systemic autoimmune rheumatic diseases. In each 
group, experts were asked to identify unmet clinical 
and translational research needs in general and then to 
prioritise and detail the most important specific needs 
within each disease area.
results Overarching themes across all disease states 
included the need to innovate clinical trial design with 
emphasis on studying patients with refractory disease, 
the development of trials that take into account disease 
endotypes and patients with overlapping inflammatory 
diseases, the need to better understand the prevalence 
and incidence of inflammatory diseases in developing 
regions of the world and ultimately to develop therapies 
that can cure inflammatory autoimmune diseases.
Conclusions Unmet needs for new therapies and trial 
designs, particularly for those with treatment refractory 
disease, remain a top priority in rheumatology.
bACkgrOund
The Advances in Targeted Therapies meeting 
(ATT) has met annually for 21 years, bringing 
together clinical scientists and immunology and 
molecular biology experts from around the world. 
The meeting focuses on clinical and translational 
research, in immune- mediated inflammatory 
diseases (IMIDs) and stimulates collaboration 
between basic scientists and clinicians. The meet-
ing’s objective is to update participants regarding 
the latest insights regarding disease mechanism(s) 
and pathophysiology and recent developments 
with both existing and novel targeted therapies 
in the field of IMIDs with a focus on rheumato-
logical diseases. Previously, a consensus document 
describing the recommended use of targeted ther-
apies within rheumatology was produced from this 
meeting.1 However, with the expanse of targeted 
therapies and the recent clinical recommendations 
published from both American College of Rheu-
matology and the European Union League Against 
Rheumatism,2–4 a document covering all targeted 
therapies across all disease indications became too 
complex and voluminous as a single manuscript. 
Accordingly, the annual meeting’s output was modi-
fied to discuss key unmet needs within the field, 
consistent with the meeting’s underlying objective 
of promoting innovation and collaboration.5 With 
the 2019 meeting, we conducted a similar process 
to review and update these unmet needs, but in this 
case, prioritise and highlight the most important 
needs in the field.
key messages
What is already known about this subject?
 ► Key unmet needs in field of rheumatology 
clinical and basic science research have been 
highlighted previously, but vary over time as the 
field progresses.
What does this study add?
 ► The Advances in Targeted Therapies meeting 
(ATT) focuses on clinical and translational 
research, in immune- mediated inflammatory 
diseases (IMIDs) and stimulates collaboration 
between basic scientists and clinicians. With 
the 2019 meeting, we reviewed, updated and 
prioritised the unmet research needs in the field
 ► This effort highlighted several overarching 
themes: the need to innovate clinical trial 
design with emphasis on studying patients 
with refractory disease, the development of 
trials that take into account disease endotypes 
and patients with overlapping inflammatory 
diseases, and the need to better understand 
the prevalence and incidence of inflammatory 
diseases in developing regions of the world.
How might this impact on clinical practice?
 ► The prioritisation and highlighting of research 
needs, particularly in aspects of clinical trial 
design, will ultimately result in improvements in 
therapy and potentially the better targeting of 
therapies toward patients with specific disease 
sub- types.
20
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MeTHOds
We assigned conference participants to disease- specific breakout 
groups which included psoriatic arthritis (PsA), rheumatoid 
arthritis (RA), axial spondyloarthritis (axSpA), systemic lupus 
erythematous (SLE) and other systemic autoimmune rheumatic 
diseases including vasculitis. Experts in each group were tasked 
with identifying unmet needs in three categorical areas: clinical 
care, clinical science and therapeutic development and basic/
translational science. A ‘facilitator’ and ‘rapporteur’ led each 
group’s discussion and summarised their results, and the groups 
were asked to highlight notable progress made towards previ-
ously identified needs as well as identify new areas of need. This 
year, each group was asked to then prioritise their discussion 
and detail the top several needs within each disease- specific area.
resulTs
rheumatoid arthritis
There was broad agreement that management of patients with 
RA who are refractory to available treatments (‘refractory’ or 
‘treatment resistant’ RA) is arguably the greatest unmet need 
in RA (at least in the developed world). However, a careful 
clinical definition of the refractory state is needed, so that we 
are not confounding true treatment- refractory disease with 
patients with RA who are undertreated, non- adherent to treat-
ment or who have comorbid fibromyalgia or other sources of 
non- inflammatory pain. Once a clinical definition of ‘refrac-
tory’ RA is achieved, a molecular definition of the refractory 
state should follow and should be differentiated from molec-
ular definitions of early RA, established RA, RA in flare and RA 
in remission. Single cell analysis of synovial and/or circulating 
cells (including gene expression) may enable us to phenotype 
RA into subgroups or states of disease.6 Molecular characteris-
tics at single cell level should be compared with whole synovial 
tissue molecular profiling with the aim of identifying periph-
eral blood surrogates of tissue pathology (liquid biopsy) and 
treatment response. The definitions of molecular subgroups 
could eventually lead to a personalised approach to treatment. 
For example, data generated may suggest that a combination 
or sequence of biologics may be efficacious in some individ-
uals. Alternatively, molecular subgrouping may identify novel 
targets proximal in the disease process—that is, in the early 
adaptive immune response—that could be targeted for drug 
development and clinical trials.
Importantly, patients who have received multiple biologics/
small molecules should not be excluded from clinical trials since 
they have the greatest unmet need. Novel targeted therapies 
should be studied in refractory patients, as should novel combi-
nations or sequences of existing therapies, similar to the way 
oncologists use checkpoint inhibitors. In particular, we should 
carefully move forward with combination therapy studies in 
refractory patients, with a commitment to resolving issues of 
cost, safety (eg, infection and malignancy) and the reluctance of 
manufacturers to combine each other’s agents. Efforts to iden-
tify optimal dosing and levels of our currently available thera-
pies, as a single treatment or in combination, are also essential to 
optimise treatment of refractory patients. Finally, it is important 
to recognise that despite many successful therapies for RA, less 
than half of patients with RA are in remission, 10%–15% are 
refractory, and there is still no cure for this disease.7–9 Continued 
commitment on the part of our funding agencies, pharmaceu-
tical partners and scientific investigators is essential to advance 
research and discovery efforts to understanding the heteroge-
neity of RA pathogenesis and effective sustainable treatments.
Psoriatic arthritis
In the last few years, there have been an increasing number of 
medications with different mechanisms of action which have 
shown benefit in PsA in randomised clinical trials and have been 
approved by regulatory agencies, including an IL12-23 inhib-
itor (ustekinumab), two IL- 17A inhibitors (secukinumab and 
ixekizumab), an oral PDE4 inhibitor (apremilast), an oral JAK 
inhibitor (tofacitinib) and abatacept.10 11 While very gratifying, 
the homogeneity imposed by clinical trial design may exclude 
important patient subgroups. For example, the great majority 
of patients have polyarticular involvement (entry criteria: 
≥3–5 inflamed joints) with few studies examining oligoartic-
ular disease (<5 inflamed joints); thus, the common oligoartic-
ular PsA represents an unmet need in PsA trials. Although the 
varied clinical domains of PsA, (eg, enthesitis, dactylitis, spondy-
litis) can show response to treatment, only a subset of patients 
demonstrate these domains and thus the measured response 
may not achieve statistical significance if the subset is too small. 
Furthermore, a domain such as PsA spondylitis, with symptom-
atic inflammatory back pain in about 15% and asymptomatic 
sacroiliitis in about 30% of patients,12 is not measured by the 
standards of axSpA trials, including centrally read MRI. The 
best way to measure oligoarticular disease in trials remains an 
unmet need, and since the oligoarticular phenotype is a common 
presentation in clinical practice, we are not able to entirely accu-
rately extrapolate results from trials to clinical practice. For 
treatment of the spondylitis component of PsA, we rely on data 
from axSpA trials, which also may not be accurately extrapolat-
able. Trials of the IL-12/23 inhibitor ustekinumab and the IL-23 
inhibitor risankizumab have failed in ankylosing spondylitis.13 
Even though these agents have demonstrated benefit and been 
approved for PsA, their ability to benefit the spinal component 
of PsA remains unproven and needs to be tested.
Phase IIIB or IV trials which specifically enrich the patient 
population for the domain or subtype in question are needed. 
Enrolment criteria could require oligoarticular disease or spon-
dylitis or enthesitis for example, although measurement tech-
niques for these disease aspects still need to be developed. Specific 
ultrasound or MRI (eg, axial clinical and imaging measures 
for a spondylitis- specific trial, entheseal- specific measures and 
imaging for an enthesitis trial) are needed. It is not clear how 
the results of these trials could be incorporated into regulatory 
labelling for the medication, but these would provide important 
clinical data helpful for clinical decision- making.
A second area of major unmet need in PsA is management 
of the therapy refractory patients who have ‘tried everything’. 
Emergence of new approved therapies will partially address this 
need, as would rational ‘combination’ studies. Clinicians are 
more frequently trying unapproved combination approaches, for 
example combining a biological medication (TNFi, IL- 17i and 
so on) with an oral agent such as a PDE4i or JAKi. Combination 
therapy trials are urgently needed, although the safety of such 
combination approaches is unknown, particularly with regard 
to infection, where a greater risk has been suggested in some 
combination trials for RA.14
A third major area of unmet need is better understanding 
of, and accounting for, the role of central sensitisation (CSS) 
(chronic widespread pain, fibromyalgia) in amplifying symptom 
severity. Recent studies have demonstrated that 15%–40% of 
patients with PsA and other rheumatic, chronic pain and inflam-
matory conditions may have concomitant CSS. When CSS is 
concomitantly present with PsA, disease activity measures which 
include patient- reported outcomes, (eg, pain, patient global) 
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are nearly twice as severe when compared with a similar PsA 
cohort that lacks CSS.15–17 Patients with PsA with concomitant 
CSS are less likely or unable to achieve targets of treatment such 
as minimal disease activity,16–18 Højgaard et al demonstrated in 
this population lack of correlation between tender entheseal 
examination and evidence of objective evidence of inflamma-
tion by ultrasound.17 18 While patients with CSS are histori-
cally excluded from PsA trials, it is difficult to exclude all such 
patients. Several measures have been developed to ascertain the 
presence of CSS/fibromyalgia;17 however, there remains a need 
for more objective biomarkers which are more feasible to use in 
clinical and trial settings. In this respect it is noteworthy, that 
the treat- to- target recommendations for PsA explicitly state that 
‘The choice of the target and of the disease activity measure 
should take comorbidities, patient factors and drug- related risks 
into account’ (recommendation #8);19 this simply means that 
an index developed for measuring disease activity in PsA should 
not be used to score a comorbid condition, alternatives will then 
have to be used. Similarly, a prerequisite for application of clas-
sification criteria for RA is that a patient has no other diagnosis, 
such as SLE.20
Ankylosing spondyloarthritis
In 2018, the spondyloarthritis discussion group identified a 
variety of unmet needs which included: understanding the rela-
tionship of peripheral disease to axial disease; early recognition 
and diagnosis of disease; understanding the causes/relationship 
of extra- articular disease including bowel and eye disease to the 
joint disease; improved imaging technologies and interpretation; 
development of biomarkers for prognosis and choice of therapy; 
a wider choice of biological therapies; an ability to improve 
prognosis (disease modifying treatment); direct comparison 
among TNF inhibitors with regard to efficacy and safety; more 
frequent disease remission; improved referral to a rheumatolo-
gist and international collaboration.21
Although this list is comprehensive, additional themes were 
identified as most important. First, the need to better understand 
the microbiome is paramount. While it is highly likely that the 
gut microbiome is contributing to the disease, we do not know 
which bacteria are most important, which portion of the bowel 
is most important, the mechanism by which the bacteria affect 
the disease, the role of non- gut microbiota, the role of non- 
bacterial microbiota or how best to therapeutically alter the gut 
microbiome as by diet of faecal transplant. Second, the failure 
to establish IL-23 as an effective therapeutic target in ankylosing 
spondylitis means that we need to understand more completely 
the IL-23- IL-17 axis and the role of IL-23 and additional cyto-
kines in the molecular pathogenesis of this disease.22–25 This 
effort should include a more complete understanding of the 
relative function of all members of the IL-17 family, including 
IL- 17F and further understanding of which cells secrete IL-17 
and why this does not seem to be under the control of IL-23 in 
this disease.26 We also need a better understanding as to how 
the disease results in both new bone formation and osteopo-
rosis.27 Unfortunately, it still takes many years in daily clinical 
practice before a diagnosis of axial SpA is made.28 29 Therefore, 
approaches for referral in primary care and for early diagnosis 
have to be further developed and implemented. Last, there is still 
further need for international agreement (and implementation) 
on nomenclature of axial SpA.30 31
systemic lupus erythematosus
Recent failures of clinical trials in SLE demonstrate weaknesses 
in current methodology and opportunities for improvement in 
multiple areas.32–37 The theme of improving clinical trial design, 
including limiting disease heterogeneity, was prioritised in 
discussion. Specifically, learning from already available data was 
deemed essential. Analysis of the primary data from completed 
clinical trials, especially combining those from several studies, 
can provide essential insights that can guide decisions for new 
studies.38 Comparing the characteristics of the patients that 
participated in the trials with the data that are available from 
independent patient registries could be helpful to identify a bias 
in trial patient selection that might help to better understand 
trial outcomes. Issues that may confound clinical trials, including 
which patients should, or perhaps more importantly, should not 
be enrolled can be addressed using this type of analysis. Further-
more, evaluation of potential outcome measures39–41 and the 
effects of background therapy or comorbidities that impact rela-
tive response to the study drug can be determined. This type 
of analysis has limitations related to which patients were actu-
ally enrolled in the trials to be analysed. Here, an appropriate 
serological test to identify autoantibody positive patients based 
on sound technology is paramount.42 43 Other datasets that may 
inform clinical trial design in different ways include patient 
registry studies, electronic medical record cohorts and admin-
istrative datasets, although issues of data quality, completeness 
and timeliness must be considered.44–47 Lupus trials are typically 
conducted with background therapy32 35 48 49 and there is little 
agreement on how this should be controlled during the conduct 
and analysis of a study.43 In fact, the ‘standard of care’ medica-
tion in SLE in general has not been defined.43 50
There are important ongoing issues surrounding the 
disease heterogeneity that also affect clinical trial design.43 
With respect to inclusion criteria, targeting a single organ or 
specific subgroup could lead to more definitive conclusions 
regarding a study drug.51 The marked variability in disease 
severity of enrolled participants could also impact the ability 
to draw conclusions.52 For example, including participants 
with low disease activity could introduce floor effects that 
limit the ability to separate placebo from active treatment. 
On the other hand, patients with the greatest need of novel 
treatment approaches, namely with life threatening disease,53 
are usually excluded from clinical trials. The impact of disease 
duration and previous treatment on the study population 
may also influence the effect of a study drug. The selected 
outcome measures can substantially influence whether a clin-
ical trial meets its intended endpoint. New potential outcome 
measures have been proposed, such as the SLE- disease activity 
score,54 intended as a continuous variable and the Lupus Low 
Disease Activity State.55 Another outcome measure, LuMOS, 
was developed from analysis of the belimumab trials and 
shows superior ability to detect change compared with the 
standard SRI-4.38 Other potentially novel outcome variables 
for this heterogeneous disease might include hierarchical 
outcomes. Using biomarkers either for inclusion or outcome 
may solve issues surrounding disease heterogeneity.
Novel trial designs that could be used for SLE include adap-
tive designs currently used in oncology.56 Drug withdrawal 
trials57 or trials that use flare for inclusion or outcome could also 
be considered as they allow the participation of patients with 
more severe disease. Novel designs might focus on reducing the 
impact of placebo response, including placebo response related 
to pretrial non- compliance.58 59 In considering targets of treat-
ment, it is tempting to focus on autoimmune inflammatory 
manifestations where exciting new discoveries provide novel 
targets.60 However, it is essential to include patient- focused 
unmet needs.61 62 These include symptoms that impact quality of 
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Table 1 Identified unmet research needs of high priority within RA, 
PSA, AxSpa, SLE and other systemic autoimmune rheumatic diseases
Rheumatoid arthritis The need to better define treatment ‘refractory’ states both 
phenotypically and molecularly
The need to focus on refractory patients in both the study 
of novel targeted therapies and in the study of existing 
therapies in novel combinations or sequences
Psoriatic arthritis Understanding differential therapeutic effects on different 
clinical domains in PsA such as enthesitis
Further evaluation of combination therapies and strategic 
trials including the use of sequential therapies, controlled 
withdrawal, the treatment of early disease and the 
treatment of monoarticular or oligoarticular disease
Ankylosing 
spondyloarthritis
Understanding the role of the microbiome in disease 
pathogenesis and potential therapy
Understanding disease pathology specifically with regard to 
why Il-23 inhibition does not improve the disease.
Systemic lupus 
erythematosus
Improving clinical trial design by reducing heterogeneity 
of participants, developing new outcome disease activity 
measures, standardising serological testing and conducting 
organ- specific trials





Improving clinical trial design, specifically with reducing 
heterogeneity in disease endotypes and the use of organ- 
specific outcome measures
Identification of predictive biomarkers and the inclusion of 
patient- reported outcomes of specific manifestations (eg, 
calcinosis) for clinical trials
axSpA, axial spondyloarthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, 
systemic lupus erythematous.
life such as pain, fatigue and cognitive dysfunction (‘lupus fog’) 
which are typically resistant to immune- focused therapies. Treat-
ments that could improve medication adherence, especially in 
socially deprived populations and by approaches which require 
less frequent dosing, or that can mitigate the important concern 
of reproductive issues, are needed. Overall, there are abundant 
opportunities for clinical scientists, pharmaceutical companies 
and regulatory bodies to collaborate towards improved method-
ology to provide better patient outcomes.
Other systemic autoimmune rheumatic diseases
This group highlighted the unmet needs primarily within 
systemic sclerosis this year, and similar to other groups, identi-
fied the issue of improving clinical trials of utmost importance. 
Recent and current clinical trials have failed to demonstrate 
efficacy for a variety of agents in the treatment of this disease, 
although the results suggest that some disease manifestations 
may actually be improved by certain agents.63 One difficulty 
in designing clinical trials to date has been the heterogeneity 
of disease manifestations. It might be appropriate to design 
trials for a specific manifestation for example (eg, lung disease). 
Alternatively an acceptable, sensitive, specific and quantitative 
combined outcome measure that would be acceptable to regula-
tory agencies could speed the design and development of trials 
for registration of new therapeutic agents.64 A dearth of predic-
tive biomarkers also makes it difficult to target drug trials to 
those with the greatest potential for benefit from specific ther-
apeutic interventions.65 66 Finally, inclusion of patient- reported 
outcomes of specific manifestations (eg, calcinosis) could allay 
patients’ concerns about entering trials.67
suMMAry
The convening of the 21st ATT afforded the possibility to discuss 
and articulate major unmet needs in the field of rheumatology, 
and across domains there were several overarching perceived 
unmet needs (table 1). It was generally understood that there has 
not been sufficient emphasis on trial designs which concentrated 
on well- defined disease subtypes. Many diseases have multiple 
subtypes (eg, axial and peripheral PsA or limited/diffuse systemic 
sclerosis with multiple serological subtypes) and trial designs 
which mix those subtypes could obscure the success of treat-
ments in specific subgroups. Likewise, trial designs which are 
able to dissect (or include) overlapping diseases are also needed.
While there has been some success in treating moderate to 
severe patients with various inflammatory rheumatic diseases 
and even inclusion of some patients with Disease Modifying 
anti- Rheumatic Drugs (DMARD)- refractory disease in RA, this 
remains a top unmet need in RA that has been even less carefully 
examined in patients with other diseases. For example, patients 
with PsA are often included in trials only if they have been naïve 
to previous conventional synthetic DMARD (csDMARDs) or 
biologic DMARD (bDMARDs); more attention needs to be paid 
to patients who are more ‘difficult- to- treat’ across all conditions, 
as well as those who have multiple complications or comorbid-
ities or those who have failed other csDMARDs or bDMARDs.
Last, while progress has been made in treating patients who 
used to have unmet need within countries and regions such as 
Australia, Japan, North America and the European Union, it was 
highlighted that more emphasis needed to be placed on under-
standing unmet needs in other countries and continents such as 
Africa, multiple areas in Asia and Central and South America.
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